Patents by Inventor Jonathan Alexander Terrett

Jonathan Alexander Terrett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1
    Patent number: 9732160
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: August 15, 2017
    Assignee: Oxford BioTherapeutics Ltd
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355599
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355587
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355592
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Treating lung cancer using human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)
    Patent number: 9505845
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: November 29, 2016
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160311903
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: March 14, 2016
    Publication date: October 27, 2016
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T.L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
    Publication number: 20160289324
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 20, 2016
    Publication date: October 6, 2016
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • ANTIBODIES ANTI MATRIPTASE FOR THE TREATMENT OF CANCER
    Publication number: 20160289338
    Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: October 6, 2016
    Inventors: Jonathan Alexander TERRETT, Chetana RAO-NAIK, Haichun HUANG, Sarah POGUE, Erika MEADDOUGH, Michelle KUHNE, Chin PAN
  • Conjugated Antibodies Against LY75 for the Treatment of Cancer
    Publication number: 20160257760
    Abstract: The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, bladder cancer, multiple myeloma and lymphoma.
    Type: Application
    Filed: October 10, 2014
    Publication date: September 8, 2016
    Inventors: Jonathan Alexander Terrett, James Edward Ackroyd
  • ANTIBODIES SPECIFIC TO CADHERIN-17
    Publication number: 20160039933
    Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.
    Type: Application
    Filed: October 5, 2015
    Publication date: February 11, 2016
    Inventors: Christian ROHLFF, Jonathan Alexander TERRETT
  • ANTIBODIES TO BONE MARROW STROMAL ANTIGEN 1
    Publication number: 20160002354
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • Anti-ROR1 antibodies and methods of use for treatment of cancer
    Patent number: 9228023
    Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: January 5, 2016
    Assignee: Oxford Biotherapeutics Ltd.
    Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
  • Monoclonal antibodies against Glypican-3
    Patent number: 9217033
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: December 22, 2015
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
  • Antibodies specific to cadherin-17
    Patent number: 9181339
    Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: November 10, 2015
    Assignee: Oxford Bio Therapeutics Ltd.
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • Antibodies to bone marrow stromal antigen 1
    Patent number: 9175092
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 3, 2015
    Assignee: OXFORD BIOTHERAPEUTICS LTD
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)
    Patent number: 9102738
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: August 11, 2015
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • ANTIBODIES
    Publication number: 20150093392
    Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CDH17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed.
    Type: Application
    Filed: November 20, 2014
    Publication date: April 2, 2015
    Inventors: Jonathan Alexander TERRETT, Christian ROHLFF
  • MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3
    Publication number: 20140186892
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
  • Monoclonal antibodies against glypican-3
    Patent number: 8680247
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: March 25, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
  • PROTEIN
    Publication number: 20140024048
    Abstract: The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.
    Type: Application
    Filed: August 9, 2013
    Publication date: January 23, 2014
    Applicant: OXFORD BIOTHERAPEUTICS, LTD.
    Inventors: Christian Rohlff, Jonathan Alexander Terrett